Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Paragon Novel Vaccine (PNV) an effective protection against all serotypes of five deadly bacteria to eradicate Antimicrobial Resistance (AMR)

Project description

Multipotent antibacterial vaccine

Antibiotic resistance is an emerging medical problem of global significance, threatening the treatment of bacterial infections using conventional drugs. Funded by the European Innovation Council, the PARAGON NOVEL VACCINE project has developed a novel immunotherapy that targets glyeraldehyde-3-phosphate dehydrogenase (GAPDH), a protein that suppresses host immunity by inducing an early production of interleukin-10, a potent anti-inflammatory cytokine. It is a peptide-based vaccine that blocks the bacterial GAPDH without interfering with the human analogue and treats infection from all invasive serotypes of five different bacterial strains. The project aims to further develop and test the innovative vaccine following promising preclinical data.

Objective

Immunethep has developed, patented (WO/2015/189422), and successfully undergone preclinical trials for a new breakthrough vaccine (PNV-Paragon Novel Vaccine). It protects against bacterial infections caused by 5 different bacteria: S. aureus, S. pneumoniae, K. pneumoniae, E. coli and GBS. Our innovation relies on the discovery of a virulence and immunosuppressive mechanism common to these pathogens. The bacteria excrete a highly immunosuppressive protein designated as glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which disables the host immune response to infection. PNV works by blocking bacterial GAPDH, while not reacting to human GAPDH, allowing the host immune system to fight infection and eliminate the bacteria. Preclinical trials demonstrated high levels of efficacy against any of the 5 bacteria with an excellent safety profile. PNV is the world’s first vaccine not only to prevent multiple bacterial infections but for all invasive serotypes, including multi-resistant strains.

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2022-ACCELERATOR-01

See all projects funded under this call

Coordinator

IMMUNETHEP
Net EU contribution
€ 2 499 999,99
Address
BIOCANT PARK, NUCLEO 4 LOTE 3
3060 197 Cantanhede
Portugal
SME
Yes
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 7 400 192,50